Treatment strategy for hypoxic-ischemic encephalopathy by regulation of prostaglandins bioactivities
Project/Area Number |
25870677
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Pediatrics
Embryonic/Neonatal medicine
|
Research Institution | Saitama Medical University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 興奮毒性 / プロスタグランジン / 神経細胞死 |
Outline of Final Research Achievements |
Hypoxic-ischemic encephalophaty(HIE) is a brain disorder caused by excitotoxicity induced neuronal death and is responsible for neonatal death, cerebral palsy and developmental disorder. Prostaglandins (PGs) are known to be upregulated in the excitotoxic insulted brain. We demonstrated that PGD2 and PGF2alpha are involved in the excitotoxicity induced neuronal death. An inhibitory treatment of PGD2 and PGF2alpha production is an important therapeutic strategy for brain damage induced by excitotoxic mechanisms such as HIE.
|
Report
(5 results)
Research Products
(30 results)